We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Large B-Cell Lymphoma

News List

FDA approves third gene therapy for large B-cell lymphoma europeanpharmaceuticalreview
February 09, 2021
Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.
Kite’s Yescarta yields positive results in ZUMA-1 trial in refractory large B-cell lymphoma pharmaceutical-business-review
December 11, 2019
Kite, a Gilead Company announced new data from the ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma.
FDA Approves Second CAR-T Cell Therapy and first for certain types of NHL americanpharmaceuticacreview
October 20, 2017
has become the second gene therapy to be approved by the US Food and Drug Administration, offering a new treatment approach for patients with certain types of large B-cell lymphoma.